Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zhiling, Zhang, Huanxin, Cao, Jiang, Zhang, Cheng, Liu, Hui, Huang, Hongming, Cheng, Hai, Qiao, Jianlin, Wang, Ying, Wang, Yan, Gao, Lei, Shi, Ming, Sang, Wei, Zhu, Feng, Li, Depeng, Sun, Haiying, Wu, Qingyun, Qi, Yuekun, Li, Hujun, Wang, Xiangmin, Li, Zhenyu, Liu, Hong, Zheng, Junnian, Qian, Wenbin, Zhang, Xi, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940756/
https://www.ncbi.nlm.nih.gov/pubmed/33708205
http://dx.doi.org/10.3389/fimmu.2021.611366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940756/
https://www.ncbi.nlm.nih.gov/pubmed/33708205
http://dx.doi.org/10.3389/fimmu.2021.611366

Ejemplares similares